Published in Antimicrob Agents Chemother on May 10, 2010
Animal models of dengue virus infection. Viruses (2012) 1.60
Functional analysis of two cavities in flavivirus NS5 polymerase. J Biol Chem (2011) 1.28
Mouse models to study dengue virus immunology and pathogenesis. Front Immunol (2014) 1.06
A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother (2012) 1.02
A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother (2010) 1.02
Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. J Virol (2011) 0.98
Inhibition of dengue virus by an ester prodrug of an adenosine analog. Antimicrob Agents Chemother (2010) 0.89
Screening of Dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay. PLoS One (2012) 0.88
Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Bioorg Med Chem (2012) 0.83
Nucleoside inhibitors of tick-borne encephalitis virus. Antimicrob Agents Chemother (2015) 0.79
Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor. Proc Natl Acad Sci U S A (2017) 0.75
Inhibitors compounds of the flavivirus replication process. Virol J (2017) 0.75
Analysis of Ribonucleotide 5'-Triphosphate Analogs as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase by Using Nonradioactive Polymerase Assays. Antimicrob Agents Chemother (2017) 0.75
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov (2017) 0.75
An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J (2002) 3.87
Infectious cDNA clone of the epidemic west nile virus from New York City. J Virol (2002) 3.21
Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol (2006) 3.07
West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. J Virol (2006) 3.07
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J Biol Chem (2001) 2.78
The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology (1991) 2.75
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J Biol Chem (2003) 2.72
Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology (1996) 2.71
A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis (2007) 2.22
An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A (2009) 2.20
The NS 3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology (1993) 2.12
Strategies for development of Dengue virus inhibitors. Antiviral Res (2010) 2.11
Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J Virol (1993) 2.06
The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem (2005) 1.75
High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother (2005) 1.73
Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother (2006) 1.72
A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother (2009) 1.59
Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev (2001) 1.46
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem (2004) 1.41
Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res (2007) 1.27
Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother (2008) 1.26
Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets (2006) 1.25
Antiviral agents acting as DNA or RNA chain terminators. Handb Exp Pharmacol (2009) 1.23
Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J Med Chem (1996) 1.16
5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved. Biochem J (2003) 1.12
Practical synthesis of a potent hepatitis C virus RNA replication inhibitor. J Org Chem (2004) 1.12
Structural basis for substrate promiscuity of dCK. J Mol Biol (2008) 1.11
2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups. J Biol Chem (2007) 1.00
Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob Agents Chemother (2002) 0.96
First example of phosphoramidate approach applied to a 4'-substituted purine nucleoside (4'-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J Med Chem (2007) 0.95
Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J Med Chem (2007) 0.95
Structure-activity studies on mammalian adenosine kinase. Biochem Biophys Res Commun (2000) 0.85
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol (2011) 4.64
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Productivity is a poor predictor of plant species richness. Science (2011) 4.21
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Valley-selective circular dichroism of monolayer molybdenum disulphide. Nat Commun (2012) 4.04
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 4.02
Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell (2011) 3.78
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Structural and electronic properties of T graphene: a two-dimensional carbon allotrope with tetrarings. Phys Rev Lett (2012) 3.30
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol (2010) 3.10
Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J Virol (2005) 3.08
West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. J Virol (2006) 3.07
Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab (2013) 3.00
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest (2011) 2.99
Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med (2006) 2.94
Structure and function of flavivirus NS5 methyltransferase. J Virol (2007) 2.93
A highly structured, nuclease-resistant, noncoding RNA produced by flaviviruses is required for pathogenicity. Cell Host Microbe (2008) 2.93
A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation (2012) 2.55
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol (2006) 2.55
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun (2010) 2.49
Super plastic bulk metallic glasses at room temperature. Science (2007) 2.45
Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell (2013) 2.43
NS5 of dengue virus mediates STAT2 binding and degradation. J Virol (2009) 2.42
The host response to West Nile Virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J Virol (2004) 2.37
Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit. Science (2002) 2.33
West Nile virus. Lancet Neurol (2007) 2.26
An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A (2009) 2.20
Strategies for development of Dengue virus inhibitors. Antiviral Res (2010) 2.11
Ivabradine significantly improves cardiac function in patients with ischemic heart disease: a meta-analysis of randomized controlled trials. Int J Cardiol (2013) 1.96
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med (2012) 1.95
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem (2010) 1.84
Ten years of dengue drug discovery: progress and prospects. Antiviral Res (2013) 1.84
Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer (2014) 1.81
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol (2004) 1.78
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res (2011) 1.75
Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol (2005) 1.75
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother (2005) 1.73
Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother (2006) 1.72
The West Nile virus mutant spectrum is host-dependant and a determinant of mortality in mice. Virology (2006) 1.72
mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res (2013) 1.72
PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev (2012) 1.66
Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J Clin Microbiol (2003) 1.65
Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64
A practical view of 'druggability'. Curr Opin Chem Biol (2006) 1.62
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother (2009) 1.59
Characterization of Burkholderia pseudomallei infection and identification of novel virulence factors using a Caenorhabditis elegans host system. Mol Microbiol (2002) 1.58
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem (2003) 1.57
West Nile virus infection of Drosophila melanogaster induces a protective RNAi response. Virology (2008) 1.56
Interaction between the cellular protein eEF1A and the 3'-terminal stem-loop of West Nile virus genomic RNA facilitates viral minus-strand RNA synthesis. J Virol (2007) 1.56
NMDA receptor activation increases free radical production through nitric oxide and NOX2. J Neurosci (2009) 1.54
RNA structures required for production of subgenomic flavivirus RNA. J Virol (2010) 1.52
ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension. J Clin Invest (2012) 1.51
Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res (2007) 1.49
Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. JAMA Surg (2013) 1.49
Distinct RNA elements confer specificity to flavivirus RNA cap methylation events. J Virol (2007) 1.48
Secondhand Smoking Is Associated With Vascular Inflammation. Chest (2015) 1.48
Epimorphic regeneration approach to tissue replacement in adult mammals. Proc Natl Acad Sci U S A (2009) 1.47
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry (2009) 1.46
Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. Urol Int (2013) 1.46
Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function. J Clin Invest (2011) 1.46
Role of the mutant spectrum in adaptation and replication of West Nile virus. J Gen Virol (2007) 1.46
Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis. J Am Acad Dermatol (2006) 1.46
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res (2013) 1.46
Granular parakeratosis of eccrine ostia. Am J Dermatopathol (2008) 1.45
Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol (2004) 1.44
West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. J Virol (2008) 1.44